A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The primary objective of the current study is to determine whether Ataciguat (HMR1766) slows progression of valve calcification in patients with moderate calcific aortic valve stenosis. Secondary and tertiary objectives are to determine whether Ataciguat slows progression of aortic valve function, reduces systemic inflammation, and prevents left ventricular dysfunction in patients with moderate calcific aortic valve stenosis.
Epistemonikos ID: 10920723a4b55bf78bcdb8fa94aec123aeaf0a4b
First added on: May 12, 2024